TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07597629: A Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6023 Combination Therapy for Unresectable Locally Advanced or Metastatic Breast Cancer

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07597629 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07597629 Rescue Dossier →